TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Reducing tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Life-quality
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 28-day transplantation-free mortality
Endpoint domain: Mortality/survival
Primary endpoint: The disease progression rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correction of posterior iris bowing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients number with AF over 30 seconds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of vomiting/retching events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Translocator protein total distribution volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Monoamine oxidase B total distribution volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Post-operative pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain state renormalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Completion of atrial fibrillation screenings by pharmacists
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abnormal rhythm detections identified by pharmacists
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physician referrals made by pharmacists
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Subjective Unit of Distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Validity of Cognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastrointestinal symptom total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change From Baseline in Body Weight Z-Score at EOT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful restoration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional tooth clinically
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healthy periapical region radiographically
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Expressing Anti-tetanus Toxoid Antibody Concentration ≥0.1 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Expressing Anti-diphtheria Toxoid Antibody Concentrations ≥0.1 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Experiencing Solicited Local Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Time to hemostasis post-mastectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Occurrence and frequency of dyskinesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: MDS-UPDRS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: WOQ-9 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: thickness of the remaining muscular layer (TRM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from documented recurrence (off-AADs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hb level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: LVMI ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients needing supplemental local anesthetic
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Perception of insufficient milk
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adverse Event recording
Endpoint domain: Adverse events/effects
Primary endpoint: Vaccine efficacy (VE) of PfSPZ Vaccine against Pf malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in the Child's fear
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Assessment of New Lesions (AK, NMSC, and Melanoma)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Application Site Skin Reactions During and Post PDT
Endpoint domain: Adverse events/effects
Primary endpoint: Early Mother-Infant Attachment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patients' acceptance rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in muscle transcriptome (direct response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in muscle transcriptome (delayed response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle glycogen depletion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Muscle glycogen resynthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUCGIR 0-2h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dialysis Adequacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Kidney Disease Quality of Life-36
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Total Fat Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total Muscle Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in anxiety symptoms using GAD-7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in depression symptoms using PHQ-9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Response Time on Stop Trials
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Frontocentral P3 Amplitude on EEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of individuals screened
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of individuals enrolled
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability based on subjective usability measure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adherence to eye exam appointments
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maximal Tolerance Dose
Endpoint domain: Adverse events/effects
Primary endpoint: Physical and psychological menstrual symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum observed plasma concentration (Cmax) of CAB and RPV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of maximum observed plasma concentration (tmax) of CAB and RPV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration - time curve from time zero to infinity (AUC[0-inf]) of CAB and RPV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reading score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Area under the curve from Hour 0 to the time of last measurable concentration (AUC0-t) of astegolimab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC extrapolated to infinity (AUC0-infinity) of astegolimab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum serum concentration (Cmax) of astegolimab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BOLD response in rmPFC to emotional stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Plasma concentrations of OXT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of VMMC's conducted in intervention vs control
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time of onset of biologic therapy in pain interference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Area of Preserved Retina
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Plasma Ornithine Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Blood Spot Ornithine Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage change in nodule volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: SAPS-H+D total score change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: (Serious) adverse events and device deficiencies
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma concentrations of Urolithin A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exposure to Urolithin A measured as area under the curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in serum Creatine Kinase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in the North Star Ambulatory Assessment scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Symptom Burden - Pain
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Quality of Life - Physical Functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: change in thigh muscle cross-sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: change in 6 min walk test (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in distal femur bone mineral density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with heart failure hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prognostic value of epicardial fat measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total left atrial strain measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Concentration of TMAO in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fasting blood glucose concentration in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency of sit/stand using Chair rise test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with AEs of special interest (AESI)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with abnormality in vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dual Task Gait Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant Acceptance of the Digital Health Coaching Program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Participant Ease of Usability of the Digital Health Coaching Program
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Feasibility of Utilizing the Digital Health Coaching Program
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of participants with Adverse Events (AE) by Seriousness and Relationship to Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Change in amblyopic eye logMAR distance VA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Forced Vital Capacity (FVC) in mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improvement in hand and finger function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Pain scores post-procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of finger mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with the Intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean change in LDL-C from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the concentration-time curve in plasma oxytocin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Induction of peptide specific T-cell responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lymph Node Swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Timing of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Safety profile of Ixovex-1
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose (MTD) of Ixovex-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Dose-limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Minimal residual disease (MRD)-negative remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Experience of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Weiss Functional Impairment Rating Scale-Parent Form
Endpoint domain: Life impact
Endpoint subdomain: Functional functioning
Primary endpoint: Self-assessment of daily time management in children (TIME-S)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of prescriptions with appropriate indications of clindamycin
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Brief pain inventory (BPI) pain severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of arthralgias
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and severity of cisplatin-induced hearing loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral blood velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Patient's satisfaction and experience during laceration repair
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient's cosmetic score of the laceration immediately after repair
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intervention Ordering Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of eligible patients randomized
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of patient with adherence to the assigned interventions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of patients with separation of mean arterial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients lost to follow-up
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of participants retained after 28 days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean difference in PROMIS Total Score from day 0 to day 28
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percent change in lactate dehydrogenase (LDH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transfusion avoidance
Endpoint domain: Adverse events/effects
Primary endpoint: Maintenance of adequate control of hemolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in quality of sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in sleep impact
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in qFibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in referral rate to clinical trials
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in accrual of minorities to clinical trials
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: CT accrual and retention due to patient navigation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Average Area Under the Plasma Concentration-time Curve (AUCinfinity) of Glipizide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hand dynamometer (Grip strength)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient rated tennis elbow evaluation (functional status)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Presence of voiding disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Acute cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Duration from randomization to disease progression
Endpoint domain: Mortality/survival
Primary endpoint: Stent optimization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peak and trough levels of apixaban
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Peak and trough levels of edoxaban
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants with Undetectable Minimal Residual Disease (uMRD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in serum potassium (sK+)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: IBS-targeted health-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Global Improvement Scale (GIS) Scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Dietary Protein Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 24 hour urinary sulfate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in prostate specific antigen (PSA) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of progression onto full sacral neuromodulation implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Presence of Biofilm in Breast Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Changes in proptosis in the study eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with adverse events receiving LASN01 compared to placebo
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with adverse events receiving LASN01
Endpoint domain: Adverse events/effects
Primary endpoint: Ipsilateral Stroke Mortality
Endpoint domain: Mortality/survival
Primary endpoint: In-stent Restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Acceptability of intervention design
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of Participants completing the exercise intervention sessions
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from Baseline in Insistence on Sameness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Microbiome dysbiosis in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbiome dysbiosis in stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to complete relief of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle tone of the upper limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Gross hand dexterity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of Plasma brain-derived Derived factor (BDNF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Level of Serum Interleukin IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects Free from Acute Aveir DR System-Related Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Free from Chronic Aveir DR System-Related Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical Dementia Rating score change
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Total Sensory Neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Monotherapy dose-limiting toxicities (DLT) rates
Endpoint domain: Adverse events/effects
Primary endpoint: Combination therapy DLT rates
Endpoint domain: Adverse events/effects